This Week in Pediatric Oncology
2014-02
Episodes
Monday Feb 10, 2014
Monday Feb 10, 2014
June
02, 2011
In this seventh episode of "This Week in
Pediatric Oncology" TWiPO podcast, host Dr. Tim Cripe interviews Dr. E.
Anders Kolb and Dr. Andrew Napper from
Nemours in Wilmington, Delaware.
This informative discussion covers the
strategies, scope, and challenges of target discovery, drug development, and
preclinical testing for pediatric cancers, a complex process that has been
accelerated by high throughput screening technology that has only recently
become available in academic settings.
Dr. Kolb is the Director of Blood and Bone
Marrow Transplantation at Alfred I. duPont Hospital for Children, and Head of
the Cancer Therapeutics Laboratory at Nemours Biomedical Research. He is also a
Principal Investigator in the Pediatric Preclinical Testing
Program (PPTP), a comprehensive program to
systematically evaluate new agents against childhood solid tumor and leukemia
models.
Dr. Andrew Napper joined the research team at
the Nemours Center for Childhood Cancer Research (NCCCR) in 2009 to establish
its High Throughput Screening and Drug Discovery Laboratory. Dr. Napper came to
Nemours from the University of Pennsylvania, where he was the Director of High
Throughput Screening for the Penn Center for Molecular Discovery, one of the
original ten centers established as part of the National Institutes of Health’s
Roadmap initiative to discover drugs for neglected diseases.
For more information on this program and
technology:
Lab Offer Hope for Kids with Cancer, Wilmington News Journal
(8/24/09)
Academic screening goes high-throughput, Nature Methods 7, 787–792
(2010)
Please send questions and comments to
twipo@solvingkidscancer.org
Monday Feb 10, 2014
Monday Feb 10, 2014
May
26, 2011
In this sixth episode of TWiPO, Dr. Tim Cripe
interviews Dr. Archie Bleyer about his career and research interest in
improving survival rates in adolescents and young adults (AYA) affected by
cancer.
Dr. Bleyer is the Medical Director of ,
Clinical Research at St. Charles Cancer Care in Bend, Oregon and a Clinical
Research Professor at Oregon Health & Sciences University in Portland. He
also is a Professor of Pediatrics at The University of Texas Medical School at
Houston and Senior Advisor of the Aflac/CureSearch Adolescent and Young Adult
Cancer Research, and founding member of the LiveStrong Young Adult Alliance.
Dr. Bleyer chaired the Children’s Cancer Group
for 10 years, then the world's largest pediatric cancer research organization,
and the Department and Division of Pediatrics at the University of Texas MD
Anderson Cancer Center. He was the American Cancer Society Professor of
Clinical Oncology and in charge of the cancer curriculum in the University of
Washington School of Medicine. During the past three decades, Dr. Bleyer was
awarded research grants totaling more than $75 million as a principal
investigator from the National Institutes of Health, the American Cancer
Society, and the Leukemia Society of America. His research has been published
in more than 300 peer-reviewed articles, chapters, and books.
This is an inspiring and enlightening
discussion of the progress and challenges of the past 3 decades of treating
children and young adults with cancer, and an optimistic view of future
improvements in survival, quality of life, and reducing late effects in
survivors. Listeners are welcome to send thoughts and comments to
twipo@solvingkidscancer.org
Monday Feb 10, 2014
Monday Feb 10, 2014
May
19, 2011
Discussion of the role of hedgehog signaling
and repositioning of drugs for pediatric cancers such as anti-fungal drug
itraconazole
In this fifth episode, hosts Dr. Tim Cripe and
Dr. Maureen O'Brien discuss the role of targeting of hedgehog signaling in
diffuse intrinsic pontine glioma (DIPG) and the use of drugs designed for other
uses -- designed for other uses -- such as itraconazole, an anti-fungal drug
found to suppress hedgehog signaling -- as a possible treatment for
medulloblastoma.
1:20 feedback and comments on previous TWiPO
episode
2:58 Hedgehog-responsive candidate cell of origin for diffuse intrinsic
pontine glioma; (fulltext) Proc Natl Acad Sci U S A. 2011
March 15; 108(11): 4453–4458
9:22 Itraconazole,
a commonly used antifungal that inhibits Hedgehog pathway activity and cancer
growth. Cancer Cell. 2010 Apr 13;17(4):388-99.
Monday Feb 10, 2014
Monday Feb 10, 2014
May
08, 2011
In this fourth episode of TWiPO host Dr. Tim
Cripe and co-host Dr. Jim Geller discuss updates after two recent meetings and
then discuss an exciting paper just published on "Tumor regression in
patients with metastatic synovial cell sarcoma and melanoma using genetically
engineered lymphocytes reactive with NY-ESO-1" J Clin Oncol. 2011 Mar
1;29(7):917-24. Epub 2011 Jan 31. by Paul Robbins and
colleagues at the NCI.
1:23 Conference
on oncolytic viruses (see recent http://vimeo.com/20002455 webinar on pediatric
trials).
7:28 Conference
on DIPG (Diffuse Intrinsic Pontine Glioma) at Cincinnati Children's; discussion
on biology, new tumor models, and genetic profiling.
12:50 Discussion
on adoptive immunotherapy using tumor-infiltrating lymphocytes in patients with
metastatic melanoma and synovial cell sarcoma.
28:28 Listener
email questions and answers. (send emails to twipo@solvingkidscancer.org)
Monday Feb 10, 2014
Monday Feb 10, 2014
April
25, 2011
In this third episode, host Tim Cripe, MD, PhD,
asks his co-hosts to discuss two recent papers that provide new information
about genetic predisposition to increased toxicity to vincristine in some
children, and the results of a phase II study using a combination therapy
(irinotecan and temozolomide) in relapsed or refractory neuroblastoma.
1:24 Maureen
O'Brien, MD discusses "Increased risk of vincristine neurotoxicity
associated with low CYP3A5 expression genotype in children with acute
lymphoblastic leukemia" in Pediatr Blood Cancer. 2011 Mar;56(3):361-7.
doi: 10.1002/pbc.22845. Epub 2010 Nov 11.http://www.ncbi.nlm.nih.gov/pubmed/21225912
22:10 Lars
Wagner, MD discusses "Phase II study of irinotecan and temozolomide in
children with relapsed or refractory neuroblastoma: a Children's Oncology Group
study" from J Clin Oncol. 2011 Jan 10;29(2):208-13. Epub 2010 Nov
29. http://www.ncbi.nlm.nih.gov/pubmed/21115869
Monday Feb 10, 2014
Monday Feb 10, 2014
April
13, 2011
In this second episode of TWiPO, host Dr. Tim
Cripe interviews Dr. Gregory Reaman about his career in pediatric oncology,
leadership of the COG, challenges, and expectations for the future.
Monday Feb 10, 2014
Monday Feb 10, 2014
April
11, 2011
Solving Kids' Cancer is sponsoring a free
podcast series for researchers, clinicians, advocates, and others focusing on
pediatric cancer research, hosted by physician-scientist Dr. Timothy Cripe and colleagues at Cincinnati Children's.
Podcasts will be published 2 to 4 times per month with discussions on new
publications, clinical trials, interviews with thought leaders, and more.
This
first episode is a discussion among the pediatric oncologists about the
recently published paper in Journal of Clinical Oncology "Outcomes for
Children and Adolescents With Cancer: Challenges for the Twenty-First
Century" (J Clin Oncol 28:2625-2634)